0001140361-23-002959.txt : 20230126 0001140361-23-002959.hdr.sgml : 20230126 20230126210117 ACCESSION NUMBER: 0001140361-23-002959 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230124 FILED AS OF DATE: 20230126 DATE AS OF CHANGE: 20230126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Rakhi CENTRAL INDEX KEY: 0001856296 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 23559450 MAIL ADDRESS: STREET 1: C/O NEUROPACE INC STREET 2: 455 N BERNARDO AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4.xml X0306 4 2023-01-24 0001635088 Roivant Sciences Ltd. ROIV 0001856296 Kumar Rakhi C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true Chief Accounting Officer Common Shares 2023-01-24 4 J 0 1838 8.56 D 134340 D Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. By: /s/ Jo Chen, as Attorney-in-Fact for Rakhi Kumar 2023-01-26